HIV clinic‐based extended‐release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non‐blinded, randomized non‐inferiority trial

BACKGROUND AND AIM: Opioid agonist medications for treatment of opioid use disorder (OUD) can improve human immunodeficiency virus (HIV) outcomes and reduce opioid use. We tested whether outpatient antagonist treatment with naltrexone could achieve similar results. DESIGN: Open‐label, non‐inferiorit...

Descripción completa

Detalles Bibliográficos
Autores principales: Korthuis, P. Todd, Cook, Ryan R., Lum, Paula J., Waddell, Elizabeth Needham, Tookes, Hansel, Vergara‐Rodriguez, Pamela, Kunkel, Lynn E., Lucas, Gregory M., Rodriguez, Allan E., Bielavitz, Sarann, Fanucchi, Laura C., Hoffman, Kim A., Bachrach, Ken, Payne, Elizabeth H., Collins, Julia A., Matthews, Abigail, Oden, Neal, Jacobs, Petra, Jelstrom, Eve, Sorensen, James L., McCarty, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314106/
https://www.ncbi.nlm.nih.gov/pubmed/35129242
http://dx.doi.org/10.1111/add.15836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314106/
https://www.ncbi.nlm.nih.gov/pubmed/35129242
http://dx.doi.org/10.1111/add.15836

Ejemplares similares